HEALTH INNOVATION VENTURES BV

Their core work

Health Innovation Ventures is a Netherlands-based SME operating at the intersection of clinical oncology research and commercial development. Their H2020 work centers on advanced cancer treatment strategies — specifically combining immunotherapy agents (such as L19-IL2, a tumor-targeting immunocytokine) with stereotactic ablative radiotherapy (SABR) for metastatic lung cancer, and applying radiomics to improve diagnostic and treatment decision-making. As a private venture, they most likely contribute commercial development expertise, clinical trial management, or technology transfer capacity to otherwise academically-led consortia. Their presence in both a randomized clinical trial (IMMUNOSABR) and a precision medicine decision-support project (PREDICT) suggests they bridge the gap between research evidence and healthcare application.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2017, which means there is no meaningful chronological shift to trace — all available keyword signal comes from the same entry point. The early-period keywords (immunotherapy, SABR, L19-IL2, lung cancer, metastatic cancer) are drawn from IMMUNOSABR, while PREDICT carried no indexed keywords despite running until 2022. Given this, any claim of evolution would be speculative; what can be said is that from the outset they pursued both direct therapeutic intervention (combination oncology) and data-driven precision medicine (radiomics), suggesting a deliberately broad oncology scope rather than a narrow niche.

With both projects originating in 2017 and no subsequent H2020 activity on record, it is unclear whether the organisation remains active in EU-funded research or has shifted to private development work — potential partners should verify current activity before approaching.

How they like to work

Health Innovation Ventures has participated exclusively as a consortium partner, never as coordinator, across its two projects. With 34 unique partners across 7 countries from just two projects, they operate within large, multi-institutional academic-clinical consortia rather than tight bilateral arrangements. This profile is typical of SMEs that plug into large research programmes to gain access to clinical data, trial infrastructure, or academic credibility while contributing commercial development or exploitation expertise.

The organisation has connected with 34 distinct partners across 7 countries through only two projects — an unusually broad network for such a small participation record. This suggests the consortia they joined were large, pan-European clinical research collaborations, likely anchored by university hospitals and cancer centres.

What sets them apart

Health Innovation Ventures occupies a rare position as a private SME inside clinical oncology research consortia — a space usually dominated by universities and hospital groups. Their dual presence in immunotherapy-radiotherapy combination trials and radiomics decision-support tools indicates they can contribute across both therapeutic and diagnostic precision oncology. For consortium builders, they offer the commercial perspective and potential exploitation pathway that academic partners typically cannot provide.

Highlights from their portfolio

• IMMUNOSABR
  The largest-funded project (€740,500) and the more specific of the two — a randomized phase II clinical trial testing L19-IL2 immunocytokine combined with SABR, representing genuine translational oncology at clinical proof-of-concept stage.
• PREDICT
  Positioned Health Innovation Ventures inside the emerging field of radiomics-based theragnostics, broadening their footprint beyond direct therapy into AI-assisted clinical decision support.